*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|
*Reference categories for clinical characteristics are individuals
without that comorbidity. Reference categories for treatments are
unexposed individuals.
AModel 1 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, biologic DMARDs, synthetic DMARDs,
, glucocorticoids, anti-hypertensive drugs and chronic NSAIDs.
BModel 2 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, TNFα antagonists, IL-6/12/17/23
antagonists, methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CModel 3 contains the following explanatory or
exposure variables: sex, age, CV disease, pulmonary disease, kidney
disease, active cancer or treatment, Adalimumab, Certolizumab,
Etanercept, Golimumab, Infliximab, anti-IL17, anti-IL12/23,
methotrexate, leflunomide, chloroquine/hydroxychloroquine,
glucocorticoids, ACE inhibitors, ARBs and chronic NSAIDs.
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs.
JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs=
non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme.
ARBs= angiotensin II receptor blockers. N=number of observations or
exposed individuals.
1Biologic DMARDs include TNF antagonists,
pro-inflammatory ILs antagonists, vedolizumab and T and B lymphocyte
antagonists.
2Synthetic DMARDs include methotrexate, JAK
inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine,
cyclosporine, chloroquine or hydroxychloroquine, leflunomide and
apremilast.
3Anti-hypertensive drugs include ACE inhibitors and
ARBs.
|